(POZN) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
June 19, 2013
This morning, Pozen (POZN) announced positive results from the company's two pivotal phase 3 clinical trials studying PA32540, a novel, coordinated-delivery tablet of immediate-release omeprazole (40mg)...(read more)
(Samurai Trader,
4/6/12)
Despite a relatively weak market, the leadership list actually had a pretty good week. There were about an equal number of gainers and decliners, but the gains far outweighed the losses. POZN was the biggest gainer, with...(read more)
Pozen Moves Higher as Analyst Suggests Buyout Possibility (POZN, AZN, AMGN, PLX, AFFY, GILD, CELG...
(tickerspy.com,
6/2/10)
Shares of POZEN (POZN) are higher today after analyst Brean Murray suggested that Pozen has become an even more attractive acquisition target following the firm's receipt of a $20 million milestone payment from AstraZeneca (AZN)...(read more)
Pozen (POZN) Company Overview
There is no analysis for POZN yet. But you can go to Wikinvest to help create one!
